Details
Сlarithromycin Indications
Treatment of infections caused by organisms susceptible to clarithromycin:
- Upper respiratory tract infection, ie nasopharyngeal (tonsillitis, pharyngitis) and infections of the paranasal sinuses;
- Lower respiratory tract infections (eg, bronchitis, acute lobar pneumonia, primary atypical pneumonia);
- Infections of the skin and soft tissues (such as impetigo, folliculitis, eryzypeloyid, abrasions, infected wounds);
- Acute and chronic odontogenic infection;
- Disseminated or localized mycobacterial infections caused by Mycobacterium avium or Mycobacterium intracellulare. Localized infection caused by Mycobacterium chelonae, Mycobacterium fortuitum or Mycobacterium kansasii;
- Eradication of H. pylori in patients with duodenal ulcer in the inhibition of secretion of hydrochloric acid (clarithromycin activity against H. pylori at neutral pH is higher than at acidic pH).
Contraindications
- Hypersensitivity to macrolide antibiotics and other ingredients.
- Concomitant use of astemizole, cisapride, pimozide, terfenadine (since it can lead to the continuation of the QT interval and development of cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation and piruetnu ventricular tachycardia (torsades de pointes)), ergot alkaloids, such as ergotamine, dihydroergotamine (as it can lead to erhotoksychnosti), inhibitors of HMG-CoA reductase inhibitors (statins), largely metabolized by CYP3A4 (lovastatin or simvastatin) because of the increased risk of myopathy, including rhabdomyolysis.
- Concomitant administration of oral midazolam and clarithromycin.
- Patients with a history of QT prolongation or ventricular cardiac arrhythmias including ventricular tachycardia piruetnu (torsades de pointes).
- Hypokalemia (risk of prolongation of the interval QT).
- Severe hepatic failure and concomitant kidney failure.
- Concomitant use of clarithromycin (and other strong inhibitors of CYP3A4) with colchicine.
- Concomitant use of clarithromycin tykahrelorom or ranolazyn.
